234 related articles for article (PubMed ID: 7629244)
1. Methimazole has no dose-related effect on the intensity of the intrathyroidal autoimmune process in relapsing Graves' disease.
Paschke R; Vogg M; Kristoferitsch R; Aktuna D; Wawschinek O; Eber O; Usadel KH
J Clin Endocrinol Metab; 1995 Aug; 80(8):2470-4. PubMed ID: 7629244
[TBL] [Abstract][Full Text] [Related]
2. Correlation of microsomal antibodies with the intensity of the intrathyroidal autoimmune process in Graves' disease.
Paschke R; Vogg M; Swillens S; Usadel KH
J Clin Endocrinol Metab; 1993 Oct; 77(4):939-43. PubMed ID: 8408468
[TBL] [Abstract][Full Text] [Related]
3. Intrathyroidal concentrations of methimazole in patients with Graves' disease.
Jansson R; Dahlberg PA; Johansson H; Lindström B
J Clin Endocrinol Metab; 1983 Jul; 57(1):129-32. PubMed ID: 6687892
[TBL] [Abstract][Full Text] [Related]
4. Predominant intraepithelial localization of primed T cells and immunoglobulin-producing lymphocytes in Graves' disease.
Paschke R; Brückner N; Schmeidl R; Pfiester P; Usadel KH
Acta Endocrinol (Copenh); 1991 Jun; 124(6):630-6. PubMed ID: 1829871
[TBL] [Abstract][Full Text] [Related]
5. The influence of iodine on the intensity of the intrathyroidal autoimmune process in Graves' disease.
Paschke R; Vogg M; Winter J; Wawschinek O; Eber O; Usadel KH
Autoimmunity; 1994; 17(4):319-25. PubMed ID: 7948614
[TBL] [Abstract][Full Text] [Related]
6. Carbimazole and the autoimmune response in Graves' disease.
McGregor AM; Petersen MM; McLachlan SM; Rooke P; Smith BR; Hall R
N Engl J Med; 1980 Aug; 303(6):302-7. PubMed ID: 6247656
[TBL] [Abstract][Full Text] [Related]
7. [Relation between the dosage of methimazole and its intrathyroidal concentrations].
Huang G
Zhonghua Yi Xue Za Zhi; 1991 Jun; 71(6):301-3, 22. PubMed ID: 1667489
[TBL] [Abstract][Full Text] [Related]
8. Effect of Graves' intrathyroidal lymphocytes. Effect of Graves' disease intrathyroidal lymphocytes (ITL) on xenotransplants of human thyroid tissue in athymic nude mice.
Schumm-Draeger PM; Jungheim K; Caspar G; Hermann G; Fortmeyer HP; Wenisch HJ; Usadel KH
Exp Clin Endocrinol Diabetes; 1996; 104 Suppl 4():60-3. PubMed ID: 8981004
[TBL] [Abstract][Full Text] [Related]
9. Similar effects of thionamide drugs and perchlorate on thyroid-stimulating immunoglobulins in Graves' disease: evidence against an immunosuppressive action of thionamide drugs.
Wenzel KW; Lente JR
J Clin Endocrinol Metab; 1984 Jan; 58(1):62-9. PubMed ID: 6196375
[TBL] [Abstract][Full Text] [Related]
10. Induction of circulating activated suppressor-like T cells by methimazole therapy for Graves' disease.
Tötterman TH; Karlsson FA; Bengtsson M; Mendel-Hartvig I
N Engl J Med; 1987 Jan; 316(1):15-22. PubMed ID: 2946953
[TBL] [Abstract][Full Text] [Related]
11. Abnormal B lymphocyte function in thyroid glands from patients with Graves' disease.
Ueki Y; Eguchi K; Otsubo T; Kawabe Y; Shimomura C; Tezuka H; Nakao H; Kawakami A; Migita K; Ishikawa
J Clin Endocrinol Metab; 1989 Nov; 69(5):939-45. PubMed ID: 2793996
[TBL] [Abstract][Full Text] [Related]
12. [The relationship between intrathyroidal dendritic cells and humoral immune disorder in Graves' disease].
Zhang HJ; Li DM; Gao DL; Zhang L; Cao J; Zhao ZH; Zhang YH; Xu L
Zhonghua Nei Ke Za Zhi; 2005 Feb; 44(2):122-4. PubMed ID: 15840225
[TBL] [Abstract][Full Text] [Related]
13. A prospective randomized trial of antithyroid drug dose in Graves' disease therapy. European Multicenter Study Group on Antithyroid Drug Treatment.
Reinwein D; Benker G; Lazarus JH; Alexander WD
J Clin Endocrinol Metab; 1993 Jun; 76(6):1516-21. PubMed ID: 8501160
[TBL] [Abstract][Full Text] [Related]
14. Immunological features of nonimmunogenic hyperthyroidism.
Grubeck-Loebenstein B; Derfler K; Kassal H; Knapp W; Krisch K; Liszka K; Smyth PP; Waldhäusl W
J Clin Endocrinol Metab; 1985 Jan; 60(1):150-5. PubMed ID: 2856880
[TBL] [Abstract][Full Text] [Related]
15. A hyperthyroid patient with Graves' disease who was strongly resistant to methimazole: investigation on possible mechanisms of the resistance.
Li H; Okuda J; Akamizu T; Mori T
Endocr J; 1995 Oct; 42(5):697-704. PubMed ID: 8574295
[TBL] [Abstract][Full Text] [Related]
16. Frequency of antineutrophil cytoplasmic antibody in Graves' disease patients treated with methimazole.
Gumà M; Salinas I; Reverter JL; Roca J; Valls-Roc M; Juan M; Olivé A
J Clin Endocrinol Metab; 2003 May; 88(5):2141-6. PubMed ID: 12727967
[TBL] [Abstract][Full Text] [Related]
17. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
Hashizume K; Ichikawa K; Sakurai A; Suzuki S; Takeda T; Kobayashi M; Miyamoto T; Arai M; Nagasawa T
N Engl J Med; 1991 Apr; 324(14):947-53. PubMed ID: 1900575
[TBL] [Abstract][Full Text] [Related]
18. The significance of antithyroglobulin and antithyroidal microsomal antibodies in patients with hyperthyroidism due to Graves' disease treated with antithyroidal drugs.
Takaichi Y; Tamai H; Honda K; Nagai K; Kuma K; Nakagawa T
J Clin Endocrinol Metab; 1989 Jun; 68(6):1097-100. PubMed ID: 2470772
[TBL] [Abstract][Full Text] [Related]
19. Lack of B7-1/BB1 and B7-2/B70 expression on thyrocytes of patients with Graves' disease. Delivery of costimulatory signals from bystander professional antigen-presenting cells.
Matsuoka N; Eguchi K; Kawakami A; Tsuboi M; Nakamura H; Kimura H; Ishikawa N; Ito K; Nagataki S
J Clin Endocrinol Metab; 1996 Nov; 81(11):4137-43. PubMed ID: 8923872
[TBL] [Abstract][Full Text] [Related]
20. The change in 123I-uptake between 3- and 24-hours is useful in predicting early response to methimazole in patients with Graves' disease.
Gemma R; Nakamura H; Mori T; Andoh S; Suzuki Y; Yoshimi T
Endocr J; 1996 Feb; 43(1):61-6. PubMed ID: 8732453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
